tiprankstipranks
Trending News
More News >
BioSig Technologies Inc (BSGM)
NASDAQ:BSGM
US Market

BioSig Technologies (BSGM) AI Stock Analysis

Compare
324 Followers

Top Page

BS

BioSig Technologies

(NASDAQ:BSGM)

34Underperform
BioSig Technologies faces significant financial difficulties, with persistent losses, high leverage, and negative cash flow trends. While technical analysis indicates some short-term momentum, potential overbought conditions warrant caution. The negative P/E ratio further underscores valuation challenges and risks associated with the stock.
Positive Factors
Growth Opportunity
The company's intention to acquire Neuro-Kinesis Corporation, which is advancing medical technology, presents a potential growth opportunity.
Market Potential
The potential billion-dollar market for PURE EP presents high rewards for the risks, making an investment in BioSig compelling.
Market Presence
The company regained its NASDAQ listing and has until March 2025 to regain full compliance, which is a positive step for its market presence.
Negative Factors
Business Operations
The company announced a major reorganization in which it terminated a significant number of its employees and substantially reduced business operations due to lack of capital.
Financial Stability
The company has ~$0 in cash and ~$0 million in debt and needs to raise new capital soon if it wants to resume business.

BioSig Technologies (BSGM) vs. S&P 500 (SPY)

BioSig Technologies Business Overview & Revenue Model

Company DescriptionBioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
How the Company Makes MoneyBioSig Technologies generates revenue primarily through the sale and lease of its PURE EP System to hospitals and medical institutions. The company also earns money by providing ongoing support services, including maintenance and upgrades, to ensure optimal performance of its systems. Additionally, BioSig may enter into strategic partnerships and collaborations with other healthcare entities and technology providers to expand its market reach and enhance its technological offerings. Key revenue streams include direct sales, leasing agreements, and service contracts associated with the PURE EP System.

BioSig Technologies Financial Statement Overview

Summary
BioSig Technologies faces significant financial challenges with a negative income statement, balance sheet, and cash flow. There are consistent losses, negative equity, and cash constraints, indicating financial instability and a need for strategic restructuring.
Income Statement
25
Negative
BioSig Technologies shows a struggling income statement with declining revenues and consistently negative net income over the years. The TTM (Trailing-Twelve-Months) data reveals a worsening gross profit margin and net profit margin, indicating financial challenges. Revenue growth is erratic, and profitability metrics such as EBIT and EBITDA margins remain negative, reflecting operational inefficiencies.
Balance Sheet
15
Very Negative
The balance sheet of BioSig Technologies presents a concerning picture with negative stockholders' equity, indicating financial distress. The debt-to-equity ratio is uncalculated due to negative equity, posing a risk of insolvency. The equity ratio is also negative, and return on equity is not meaningful due to sustained losses, highlighting the company's weak financial stability.
Cash Flow
30
Negative
The cash flow statement reveals a negative free cash flow growth, although there is a slight improvement in operating cash flow relative to net income. However, free cash flow remains significantly negative, indicating ongoing cash burn. The reliance on financing activities for liquidity demonstrates a lack of sustainable cash generation from operations.
Breakdown
Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
18.00K286.00K441.00K0.000.00
Gross Profit
18.00K229.00K242.00K-550.00K-54.35K
EBIT
-28.51M-27.27M-33.41M-59.18M-34.60M
EBITDA
-28.15M-26.97M-33.21M-58.63M-34.42M
Net Income Common Stockholders
-29.04M-27.27M-31.36M-52.17M-33.92M
Balance SheetCash, Cash Equivalents and Short-Term Investments
190.00K458.00K11.66M28.27M12.11M
Total Assets
1.80M4.11M15.52M30.39M14.22M
Total Debt
452.00K765.00K656.00K314.00K723.42K
Net Debt
262.00K408.00K-11.00M-27.95M-11.39M
Total Liabilities
4.68M3.71M2.95M5.11M2.34M
Stockholders Equity
-2.91M418.00K12.35M24.48M11.36M
Cash FlowFree Cash Flow
-17.50M-21.87M-26.94M-26.69M-15.77M
Operating Cash Flow
-17.31M-21.70M-26.40M-26.60M-15.48M
Investing Cash Flow
-186.00K-168.00K-542.00K-87.00K-285.93K
Financing Cash Flow
17.33M10.57M10.33M42.85M23.43M

BioSig Technologies Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.03
Price Trends
50DMA
0.72
Positive
100DMA
0.97
Positive
200DMA
0.86
Positive
Market Momentum
MACD
0.10
Negative
RSI
72.74
Negative
STOCH
79.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BSGM, the sentiment is Positive. The current price of 1.03 is above the 20-day moving average (MA) of 0.70, above the 50-day MA of 0.72, and above the 200-day MA of 0.86, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 72.74 is Negative, neither overbought nor oversold. The STOCH value of 79.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BSGM.

BioSig Technologies Risk Analysis

BioSig Technologies disclosed 51 risk factors in its most recent earnings report. BioSig Technologies reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

BioSig Technologies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$5.28B3.75-42.72%2.86%17.70%2.03%
46
Neutral
$16.08M-266.25%8.91%70.18%
42
Neutral
$12.25M-53.65%-88.70%-3.48%
40
Underperform
$14.08M-499.57%22.15%
34
Underperform
$24.98M5400.35%122.22%79.08%
34
Underperform
$12.86M110.26%-2.99%59.87%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BSGM
BioSig Technologies
1.22
-0.49
-28.65%
AXDX
Accelerate Diagnostics
0.51
-0.41
-44.57%
CODX
Co-Diagnostics
0.36
-0.85
-70.25%
PAVM
PAVmed
0.82
-1.25
-60.39%
VVOS
Vivos Therapeutics
2.73
0.10
3.80%
ADGM
Adagio Medical Holdings
1.26
-10.08
-88.89%

BioSig Technologies Corporate Events

Executive/Board ChangesShareholder MeetingsStock Split
BioSig Technologies Shareholders Support Strategic Proposals
Positive
Dec 31, 2024

BioSig Technologies held its Annual Meeting where four key proposals were submitted to stockholders for voting. The proposals included electing five directors to the board, approving a reverse stock split, increasing shares under the Incentive Plan, and ratifying Marcum LLP as the independent accounting firm. The votes resulted in the election of directors, approval of the reverse stock split and Incentive Plan Amendment, and ratification of the accounting firm, reflecting shareholder support for the company’s strategic decisions.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.